Please login to the form below

Not currently logged in
Email:
Password:

Merck ends Alzheimer’s deal, partners with Exelixis

Terminates agreement with Acumen and switches focus to R&D programme for inflammation and oncology

Merck & Co has terminated an agreement with Acumen to develop treatments for Alzheimer's disease the same day it announced it has bought the licence to an R&D programme from Exelixis.

US biotech Acumen said Merck abandoned the Alzheimer's agreement due to 'internal strategic priorities'.

The deal, originally agreed in 2003, was to develop and commercialise anti-ADDL antibody therapeutics.

Recent pre-clinical development of compounds had seen failures of a gamma secretase inhibitor, however, and little success had been seen in the efficacy of non-selective amyloid beta immunotherapies, according to Dr Franz Hefti, Acumen's newly announced president and CEO.

Despite Merck's decision to pull out of the deal, Hefti was still positive about the programme's potential.

He said: "Our Merck colleagues successfully advanced anti-ADDL antibody therapeutics to a late pre-clinical development stage based on antibodies that we believe will allow Acumen to develop a best in class, disease modifying therapy for Alzheimer's disease."

Separately, Merck is to enter a deal with Exelixis to gain exclusive worldwide licence to its PI3K-delta R&D programme.

Exelixis, another US biotech, will receive an upfront payment of $12m from Merck and will be eligible for potential development and regulatory milestone payments of up to $239m. Sales milestones are also available.

The programme covers several therapeutic areas, including inflammation and oncology.

Products in development as part of the programme include PI3K-delta inhibitor XL499.

The compounds aims to control the PI3K-delta kinase, overactivation of which is thought to lead to multiple inflammatory and allergic disorders, and certain forms of lymphona.

Dr Don Nicholson, vice president and head of Worldwide Discovery, Respiratory and Immunology Franchise, Merck Research Laboratories, said: “Exelixis has established a strong reputation for innovation in the development of targeted kinase inhibitors.

“Collaborations like this are an important part of our strategy as we seek new ways to address unmet needs in inflammatory disease and oncology.”

22nd December 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Emotion-driven clinical trial marketing: A missed opportunity?
Whether we’re conscious of it or not, our emotions play a huge role in day-to-day decision making. Psychological scientists have long explored emotional influences on decision making. Experts like Herbert...
Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...

Infographics